Smith & Nephew Biologics new Joint Venture with Essex Woodlands – An Interview with Mark Augusti (OrthoSpineNews)
We recently heard the news about Smith & Nephew selling 51% of their Biologics division to Essex Woodlands in a Joint Venture. We caught up with the new President and CEO of the new company and got his thoughts on the news.
Interview with Mark Augusti, CEO Bioventus LLC.
Drue De Angelis: Mark, thanks for taking some time with us today. Could you give us your brief background and how did you end up where you are today?
Mark Augusti: I joined GE Medical Systems right out of earning a Degree from Duke University. I was in the imaging business for a number of years, and I had a foray into investment banking from 2000 to 2002. I joined Smith & Nephew in April of 2003 as the Global VP of Marketing for the trauma business, and I’ve been with them since Friday of last week (May 4), when I transferred over as CEO of Bioventus at midnight on May 5th. At Smith & Nephews I had various orthopedic roles, going from VP to general manager, to President. I’ve been involved with our clinical therapies business, which was EXOGEN and SUPARTZ, in-and-out of the trauma busi...
